Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data

Bibliography

• Stewart BW, Kleihaus P. World Cancer Report 2003. IARC Press, Lyon, France; 2003
   Google Scholar
• Hubel K, Engert A. Clinical applications of granulocyte colony-stimulating factor: an update and summary. Ann Hematol 2003;82:207-13
   PubMed Web of Science ®Google Scholar
• Welte K, Gabrilove J, Bronchud MH, Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996;88:1907-29
   PubMed Web of Science ®Google Scholar
• Wong GG, Witek JS, Temple PA, Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 1985;228:810-5
   PubMed Web of Science ®Google Scholar
• Nagata S, Tsuchiya M, Asano S, Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 1986;319:415-8
   PubMed Web of Science ®Google Scholar
• Tani K, Ozawa K, Ogura H, Implantation of fibroblasts transfected with human granulocyte colony-stimulating factor cDNA into mice as a model of cytokine-supplement gene therapy. Blood 1989;74:1274-80
   PubMed Web of Science ®Google Scholar
• Ataergin S, Arpaci F, Turan M, Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol 2008;83:644-8
   PubMed Web of Science ®Google Scholar
• Holig K, Kramer M, Kroschinsky F, Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009;114:3757-63
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
   PubMed Web of Science ®Google Scholar
• Aapro MS, Cameron DA, Pettengell R, EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-53
   PubMed Web of Science ®Google Scholar
• Kubota N, Orita T, Hattori K, Structural characterization of natural and recombinant human granulocyte colony-stimulating factors. J Biochem 1990;107:486-92
   PubMed Web of Science ®Google Scholar
• Nissen C. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. Eur J Cancer 1994;30A(Suppl 3):S12-4
   PubMedGoogle Scholar
• Oh-eda M, Hasegawa M, Hattori K, O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem 1990;265:11432-5
   PubMed Web of Science ®Google Scholar
• Wang C, Eufemi M, Turano C, Giartosio A. Influence of the carbohydrate moiety on the stability of glycoproteins. Biochemistry 1996;35:7299-307
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Gibelli N, Pavesi L, Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells. Anticancer Res 1996;16:1781-5
   PubMed Web of Science ®Google Scholar
• Querol S, Cancelas JA, Amat L, Effect of glycosylation of recombinant human granulocytic colony-stimulating factor on expansion cultures of umbilical cord blood CD34+ cells. Haematologica 1999;84:493-8
   PubMedGoogle Scholar
• Nohynek GJ, Plard JP, Wells MY, Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats. Cancer Chemother Pharmacol 1997;39:259-66
   PubMed Web of Science ®Google Scholar
• Tanaka H, Tanaka Y, Shinagawa K, Three types of recombinant human granulocyte colony-stimulating factor have equivalent biological activities in monkeys. Cytokine 1997;9:360-9
   PubMed Web of Science ®Google Scholar
• Bonig H, Silbermann S, Weller S, Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)–results of a prospective randomised monocentre study. Bone Marrow Transplant 2001;28:259-64
   PubMed Web of Science ®Google Scholar
• Hoglund M, Smedmyr B, Bengtsson M, Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers–a comparative study. Eur J Haematol 1997;59:177-83
   PubMed Web of Science ®Google Scholar
• Watts MJ, Addison I, Long SG, Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol 1997;98:474-9
   PubMed Web of Science ®Google Scholar
• Houston AC, Stevens LA, Cour V. Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers. Br J Clin Pharmacol 1999;47:279-84
   PubMed Web of Science ®Google Scholar
• Johnston E, Crawford J, Blackwell S, Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522-8
   PubMed Web of Science ®Google Scholar
• Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004;10:1235-44
   PubMed Web of Science ®Google Scholar
• Terashi K, Oka M, Ohdo S, Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients. Antimicrob Agents Chemother 1999;43:21-4
   PubMed Web of Science ®Google Scholar
• Akizuki S, Mizorogi F, Inoue T, Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects. Bone Marrow Transplant 2000;26:939-46
   PubMed Web of Science ®Google Scholar
• Takatani H, Soda H, Fukuda M, Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts. Antimicrob Agents Chemother 1996;40:988-91
   PubMed Web of Science ®Google Scholar
• Dunn CJ, Goa KL. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 2000;59:681-717
   PubMed Web of Science ®Google Scholar
• Huttmann A, Schirsafi K, Seeber S, Bojko P. Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. J Cancer Res Clin Oncol 2005;131:152-6
   PubMed Web of Science ®Google Scholar
• Carulli G, Mattii L, Azzara A, Actin polymerization in neutrophils from donors of peripheral blood stem cells: divergent effects of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factor. Am J Hematol 2006;81:318-23
   PubMed Web of Science ®Google Scholar
• Avalos BR, Gasson JC, Hedvat C, Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. Blood 1990;75:851-7
   PubMed Web of Science ®Google Scholar
• Fossat C, Stoppa AM, Sainty D, In vivo stimulation of neutrophil function by lenograstim (glycosylated rHuG-CSF) in oncohematologic patients: results of a phase I trial. Stem Cells 1994;12:322-8
   PubMed Web of Science ®Google Scholar
• Ribeiro D, Veldwijk MR, Benner A, Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim. Transfusion 2007;47:969-80
   PubMed Web of Science ®Google Scholar
• Turzanski J, Crouch SP, Fletcher J, Hunter A. Ex vivo neutrophil function in response to three different doses of glycosylated rHuG-CSF (Lenograstim). Br J Haematol 1997;96:46-54
   PubMed Web of Science ®Google Scholar
• Ono M. Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim). Eur J Cancer 1994;30A(Suppl 3):S7-11
   PubMedGoogle Scholar
• Anderlini P. Effects and safety of granulocyte colony-stimulating factor in healthy volunteers. Curr Opin Hematol 2009;16:35-40
   PubMed Web of Science ®Google Scholar
• Ikonomidis I, Papadimitriou C, Vamvakou G, Treatment with granulocyte colony stimulating factor is associated with improvement in endothelial function. Growth Factors 2008;26:117-24
   PubMed Web of Science ®Google Scholar
• Wang QR, Wang F, Zhu WB, GM-CSF accelerates proliferation of endothelial progenitor cells from murine bone marrow mononuclear cells in vitro. Cytokine 2009;45:174-8
   PubMed Web of Science ®Google Scholar
• Frampton JE, Yarker YE, Goa KL. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings. Drugs 1995;49:767-93
   PubMed Web of Science ®Google Scholar
• Martino M, Console G, Dattola A, Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience. Bone Marrow Transplant 2009;44:163-8
   PubMed Web of Science ®Google Scholar
• Takagi T, Sawamura M, Sezaki T, Clinical benefits of lenograstim in patients with neutropenia due to chemotherapy for multiple myeloma (MM). Support Care Cancer 2001;9:397-9
   PubMed Web of Science ®Google Scholar
• Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 2005;3:557-71
   PubMedGoogle Scholar
• Chevallier B, Chollet P, Merrouche Y, Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13:1564-71
   PubMed Web of Science ®Google Scholar
• Martin M, Lluch A, Segui MA, Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006;17:1205-12
   PubMed Web of Science ®Google Scholar
• Amadori S, Suciu S, Jehn U, Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005;106:27-34
   PubMed Web of Science ®Google Scholar
• Bradstock K, Matthews J, Young G, Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia 2001;15:1331-8
   PubMed Web of Science ®Google Scholar
• Culine S, Romieu G, Fabbro M, Reducing the time interval between cycles using standard doses of docetaxel and lenogastrim support: a feasibility study. Cancer 2004;101:178-82
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Favaretto A, Boni L, Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter Phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis–a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 2005;23:569-75
   PubMed Web of Science ®Google Scholar
• Woll PJ, Hodgetts J, Lomax L, Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995;13:652-9
   PubMed Web of Science ®Google Scholar
• Heigener DF, Manegold C, Jager E, Multicenter randomized open-label Phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in “extensive disease” stage. Am J Clin Oncol 2009;32:61-4
   PubMed Web of Science ®Google Scholar
• Thatcher N, Girling DJ, Hopwood P, Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 2000;18:395-404
   PubMed Web of Science ®Google Scholar
• Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002;112:406-11
   PubMed Web of Science ®Google Scholar
• Doorduijn JK, van der HB, van Imhoff GW, CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041-50
   PubMed Web of Science ®Google Scholar
• Juan O, Campos JM, Caranana V, A randomized, crossover comparison of standard-dose versus low-dose lenograstim in the prophylaxis of post-chemotherapy neutropenia. Support Care Cancer 2001;9:241-6
   PubMed Web of Science ®Google Scholar
• Toner GC, Shapiro JD, Laidlaw CR, Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison. J Clin Oncol 1998;16:3874-9
   PubMed Web of Science ®Google Scholar
• Hara T, Tsurumi H, Kasahara S, Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness. Int J Hematol 2005;82:430-6
   PubMed Web of Science ®Google Scholar
• Hashino S, Morioka M, Irie T, Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma. Int J Lab Hematol 2008;30:292-9
   PubMed Web of Science ®Google Scholar
• Chantepie S, Gunzer K, Le Stang N, Joly F. Course of granulocyte colony stimulating factor (lenograstim) every two days for patients with prolonged moderate neutropenia during chemotherapy for solid tumor allows conservation of dose intensity. MAASC 18ème symposium international, Toronto, Juin 2006
   Google Scholar
• Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402-9
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Mayordomo JI, Tornamira MV, Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001;93:31-8
   PubMed Web of Science ®Google Scholar
• Clark OA, Lyman GH, Castro AA, Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:4198-214
   PubMed Web of Science ®Google Scholar
• Berghmans T, Paesmans M, Lafitte JJ, Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002;10:181-8
   PubMed Web of Science ®Google Scholar
• Shochat E, Rom-Kedar V. Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling. Clin Cancer Res 2008;14:6354-63
   PubMed Web of Science ®Google Scholar
• Takeyama K, Ogura M, Morishima Y, A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. Jpn J Clin Oncol 2003;33:78-85
   PubMed Web of Science ®Google Scholar
• Kim S, Kim HJ, Park JS, Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol 2005;84:742-7
   PubMed Web of Science ®Google Scholar
• Schmitz N, Ljungman P, Cordonnier C, Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplant 2004;34:955-62
   PubMed Web of Science ®Google Scholar
• Suh C, Kim HJ, Kim SH, Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses. Transfusion 2004;44:533-8
   PubMed Web of Science ®Google Scholar
• Jang G, Ko OB, Kim S, Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma. Transfusion 2008;48:640-6
   PubMed Web of Science ®Google Scholar
• Valteau-Couanet D, Faucher C, Auperin A, Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone Marrow Transplant 2005;36:547-52
   PubMed Web of Science ®Google Scholar
• Nolan L, Lorigan P, Chilton S, Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue. Br J Haematol 2007;137:436-42
   PubMed Web of Science ®Google Scholar
• Kopf B, De Giorgi U, Vertogen B, A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant 2006;38:407-12
   PubMed Web of Science ®Google Scholar
• Morishita M, Leonard RC. Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy. Expert Opin Biol Ther 2008;8:993-1001
   PubMed Web of Science ®Google Scholar
• Veyret C, Levy C, Chollet P, Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer 2006;107:2535-44
   PubMed Web of Science ®Google Scholar
• Okazaki T, Ebihara S, Asada M, Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int Immunol 2006;18:1-9
   PubMed Web of Science ®Google Scholar
• Shojaei F, Wu X, Qu X, G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 2009;106:6742-7
   PubMed Web of Science ®Google Scholar